Sugi Predict

Sugi Predict / Compounds / SCHEMBL6138949

SCHEMBL6138949

SCHEMBL6138949

COCCOCCOC(=O)CCCCC(=O)c1ccc(-c2cc(C)cs2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNFRSF1A P19438 3/20 0.37
▸ ABCB11 O95342 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ ADRA2B P18089 1/20 0.37
▸ OPRD1 P41143 1/20 0.37
▸ SCN5A Q14524 1/20 0.37
▸ SLC6A7 Q99884 1/20 0.36
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ CHEK1 O14757 1/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ CTNNB1 P35222 2/20 0.34
▸ L3MBTL1 Q9Y468 3/20 0.34
▸ LMNA P02545 2/20 0.33
▸ HDAC1 Q13547 2/20 0.33
▸ GALR3 O60755 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CSF1R P07333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6138868 0.82 CTNNB1 (0.34) ABCB11CYP3A4ADRA2BOPRD1SCN5A
SCHEMBL6138900 0.78 HDAC1 (0.49) ABCB11CYP3A4ADRA2BOPRD1SCN5A
SCHEMBL6138941 0.77 HAO1 (0.44) ABCB11CYP3A4ADRA2BOPRD1SCN5A
SCHEMBL6138955 0.74 MAPT (0.49) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL6138774 0.73 KCNMA1 (0.50) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL2304415 0.70 DGKA (0.57) ABCB11CYP3A4ADRA2BOPRD1SCN5A
SCHEMBL9903608 0.70 DGKA (0.57) ABCB11CYP3A4ADRA2BOPRD1SCN5A
SCHEMBL9903196 0.70 DGKA (0.57) ABCB11CYP3A4ADRA2BOPRD1SCN5A
SCHEMBL17998754 0.70 DGKA (0.57) ABCB11CYP3A4ADRA2BOPRD1SCN5A
SCHEMBL17084549 0.70 DGKA (0.57) ABCB11CYP3A4ADRA2BOPRD1SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1215203-B1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2005-02-16 — — EP disclosed
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-10-28 — — US disclosed
US-6770644-B1 Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient ONO PHARMACEUTICALS CO., LTD. (JP) 2004-08-03 — — US disclosed
EP-1215203-A1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient HIF1AN, IL6, PYGM TNFRSF1A 151/4885ABCB11 3773/4885CYP3A4 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.